{"transactions":[{"id":731794,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:30:44.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276144","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000119312526276144/ownership.xml","form_type":"4"}},{"id":800275,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Option vested in full in connection with consummation of the Merger."}],"balance_after":0,"derivative":{"exercise_price":5.96,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":74872},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800274,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42467,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.27,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":42467},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800273,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30474,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.62,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":30474},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800272,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.55,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":45423},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800271,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36111,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.71,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":36111},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800270,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.81,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":18574},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800269,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19473,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2029-06-27","underlying":"Common Stock","underlying_shares":19473},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800268,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.6,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":16236},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800267,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with consummation of the Merger, each reported stock option (\"Option\") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.71,"expiration_date":"2026-06-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":800266,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-27T20:42:13.000Z","date":"2026-04-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":142564,"price":14.5,"value":2067178.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the \"Merger\"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-182278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000119312526182278/ownership.xml","form_type":"4"}},{"id":890380,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-02-21T00:47:36.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."}],"balance_after":8300,"derivative":{"exercise_price":28.06,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001933414-26-000044","document":"wk-form4_1771634854.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000193341426000044/wk-form4_1771634854.xml","form_type":"4"}},{"id":890379,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-21T00:47:36.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":6200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant."}],"balance_after":6200,"source":{"system":"sec-edgar","filing":"0001933414-26-000044","document":"wk-form4_1771634854.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000193341426000044/wk-form4_1771634854.xml","form_type":"4"}},{"id":944175,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-08T02:12:50.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the option vest on the first anniversary measured from January 5 2026 (the \"Vesting Commencement Date\"), and 1/36th of the total number of shares vest in twenty-four (24) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":45000,"derivative":{"exercise_price":7.3,"expiration_date":"2036-01-04","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-26-006809","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000119312526006809/ownership.xml","form_type":"4"}},{"id":1120055,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2025-06-06T20:58:02.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":74872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":74872,"derivative":{"exercise_price":5.96,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":74872},"source":{"system":"sec-edgar","filing":"0000950170-25-083220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017025083220/ownership.xml","form_type":"4"}},{"id":1120054,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:58:02.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":20414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":115857,"source":{"system":"sec-edgar","filing":"0000950170-25-083220","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017025083220/ownership.xml","form_type":"4"}},{"id":1249209,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-02-24T23:58:30.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":32900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 substantially equal monthly installments following the date of grant."}],"balance_after":32900,"derivative":{"exercise_price":10.2,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":32900},"source":{"system":"sec-edgar","filing":"0001933414-25-000012","document":"wk-form4_1740441504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000193341425000012/wk-form4_1740441504.xml","form_type":"4"}},{"id":1487249,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-06-07T23:46:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":42467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":42467,"derivative":{"exercise_price":10.27,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":42467},"source":{"system":"sec-edgar","filing":"0000950170-24-071004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024071004/ownership.xml","form_type":"4"}},{"id":1487248,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T23:46:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":11847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":95443,"source":{"system":"sec-edgar","filing":"0000950170-24-071004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024071004/ownership.xml","form_type":"4"}},{"id":1503399,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-05-23T20:22:16.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting."}],"balance_after":22000,"derivative":{"exercise_price":12.52,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001933414-24-000022","document":"wk-form4_1716495708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000193341424000022/wk-form4_1716495708.xml","form_type":"4"}},{"id":1584624,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2024-03-11T21:36:29.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the options were fully vested and exercisable as of the transaction date."}],"balance_after":0,"derivative":{"exercise_price":2.8,"expiration_date":"2024-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-029458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024029458/ownership.xml","form_type":"4"}},{"id":1584623,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T21:36:29.000Z","date":"2024-03-07","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":2.8,"value":42000.0,"ownership":{"direct":true},"balance_after":83596,"source":{"system":"sec-edgar","filing":"0000950170-24-029458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000095017024029458/ownership.xml","form_type":"4"}},{"id":1743649,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":72.74,"underlying":"Common Stock","underlying_shares":2966},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743648,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":82.25,"underlying":"Common Stock","underlying_shares":2174},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743647,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2748,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":85.12,"underlying":"Common Stock","underlying_shares":2748},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743646,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2036,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":122.01,"underlying":"Common Stock","underlying_shares":2036},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743645,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1598,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":145.22,"underlying":"Common Stock","underlying_shares":1598},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743644,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":183.62,"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743643,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":551,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof"}],"balance_after":0,"derivative":{"exercise_price":210.36,"underlying":"Common Stock","underlying_shares":551},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743642,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12547,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.17,"underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743641,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.82,"underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743640,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":17.08,"underlying":"Common Stock","underlying_shares":12089},"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743639,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8111,"price":19,"value":154109.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1743638,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:45:58.000Z","date":"2023-11-08","kind":"other","planned":false,"acquired":false,"shares":23447,"price":19,"value":445493.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. (\"Alfasigma\"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117109","document":"tm2330435-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117109/tm2330435-6_4seq1.xml","form_type":"4"}},{"id":1780865,"issuer":{"id":4432,"kind":"organization","name":"Mineralys Therapeutics, Inc.","symbol":"MLYS"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-09-14T20:13:33.000Z","date":"2023-09-13","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 36 monthly installments beginning on October 13, 2023."}],"balance_after":44000,"derivative":{"exercise_price":12.02,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001933414-23-000078","document":"wf-form4_169472239867794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277478/000193341423000078/wf-form4_169472239867794.xml","form_type":"4"}},{"id":1830212,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":22.57,"expiration_date":"2032-12-19","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830211,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":252000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":14.83,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":252000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830210,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":293150,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":7.5,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":293150},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830209,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":5.22,"expiration_date":"2029-12-08","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830208,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":133500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":1.45,"expiration_date":"2028-12-11","underlying":"Common Stock","underlying_shares":133500},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830207,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830206,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":260000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.52,"expiration_date":"2027-01-29","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830205,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":44.9,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830204,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":48.3,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830203,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":37,"expiration_date":"2024-05-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830202,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6949,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock (\"IVERIC Option\") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":33.27,"expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":6949},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830201,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830200,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":94500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830199,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73315,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":73315},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830198,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each IVERIC restricted stock unit (\"RSU\") represented the contingent right to receive one share of Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23750},"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1830197,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-07-13T13:59:06.000Z","date":"2023-07-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":239275,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 11, 2023, pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated April 28, 2023, by and among IVERIC bio, Inc. (\"IVERIC\"), Astellas US Holding, Inc., Berry Merger Sub, Inc. (\"Merger Sub\") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. (\"Astellas\"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each share of IVERIC common stock (\"Common Stock\") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-080686","document":"tm2321002-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465923080686/tm2321002-7_4seq1.xml","form_type":"4"}},{"id":1844124,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-26T16:44:48.000Z","date":"2023-06-22","kind":"exercise","planned":false,"acquired":false,"shares":11084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 9, 2013 under the Registrant's 2007 Stock Incentive Plan  and vested in monthly increments for a period of 36 months from the date of the grant."}],"balance_after":0,"derivative":{"exercise_price":13.216,"expiration_date":"2023-07-08","underlying":"Common Stock","underlying_shares":11084},"source":{"system":"sec-edgar","filing":"0001410939-23-000099","document":"wk-form4_1687812280.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000099/wk-form4_1687812280.xml","form_type":"4"}},{"id":1844123,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-06-26T16:44:48.000Z","date":"2023-06-22","kind":"exercise","planned":false,"acquired":true,"shares":11084,"price":13.216,"value":146486.144,"ownership":{"direct":true},"balance_after":239275,"source":{"system":"sec-edgar","filing":"0001410939-23-000099","document":"wk-form4_1687812280.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000099/wk-form4_1687812280.xml","form_type":"4"}},{"id":1859201,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2023-06-12T21:37:13.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":30474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":30474,"derivative":{"exercise_price":12.62,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":30474},"source":{"system":"sec-edgar","filing":"0001209191-23-036418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123036418/doc4.xml","form_type":"4"}},{"id":1859200,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T21:37:13.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":8584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":95303,"source":{"system":"sec-edgar","filing":"0001209191-23-036418","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123036418/doc4.xml","form_type":"4"}},{"id":1877854,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-05-25T20:40:31.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":12547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":12547,"derivative":{"exercise_price":9.17,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-064845","document":"tm2317083-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064845/tm2317083-8_4seq1.xml","form_type":"4"}},{"id":1877853,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:40:31.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":8111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":31558,"source":{"system":"sec-edgar","filing":"0001104659-23-064845","document":"tm2317083-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064845/tm2317083-8_4seq1.xml","form_type":"4"}},{"id":1885128,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2023-05-19T21:13:59.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the options were fully vested and exercisable as of the transaction date."}],"balance_after":0,"derivative":{"exercise_price":3.32,"expiration_date":"2023-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-031103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123031103/doc4.xml","form_type":"4"}},{"id":1885127,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T21:13:59.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":3.32,"value":49800.0,"ownership":{"direct":true},"balance_after":86719,"source":{"system":"sec-edgar","filing":"0001209191-23-031103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919123031103/doc4.xml","form_type":"4"}},{"id":2066836,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2023-01-04T18:34:05.000Z","date":"2023-01-02","kind":"exercise","acquired":false,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 16, 2021, the Reporting Person was granted 126,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 16, 2021, the Reporting Person was granted 126,000 restricted stock units, which vests with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026), subject to continued employment with the Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan."}],"balance_after":94500,"derivative":{"underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001410939-23-000008","document":"wf-form4_167287522283174.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000008/wf-form4_167287522283174.xml","form_type":"4"}},{"id":2066835,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-04T18:34:05.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":17447,"price":20.06,"value":349986.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on January 2, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $19.91 to $20.56 on January 3, 2023 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":228191,"source":{"system":"sec-edgar","filing":"0001410939-23-000008","document":"wf-form4_167287522283174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000008/wf-form4_167287522283174.xml","form_type":"4"}},{"id":2066834,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-04T18:34:05.000Z","date":"2023-01-02","kind":"exercise","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit."}],"balance_after":245638,"source":{"system":"sec-edgar","filing":"0001410939-23-000008","document":"wf-form4_167287522283174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093923000008/wf-form4_167287522283174.xml","form_type":"4"}},{"id":2074886,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-29T16:50:55.000Z","date":"2022-12-27","kind":"gift","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 27, 2022, the Reporting Person gifted a total of 30,000 shares of Registrant's common stock to three trusts of which the Reporting Person's immediate family members are the sole trustees and sole beneficiaries.  The Reporting Person does not share a primary residence with any of the trustees or beneficiaries of these trusts and does not have a reportable beneficial interest in these shares."}],"balance_after":214138,"source":{"system":"sec-edgar","filing":"0001410939-22-000152","document":"wf-form4_167235064050943.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000152/wf-form4_167235064050943.xml","form_type":"4"}},{"id":2077571,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-12-22T18:56:00.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2024, January 2, 2025, January 2, 2026 and January 2, 2027)."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001410939-22-000150","document":"wf-form4_167175334409918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000150/wf-form4_167175334409918.xml","form_type":"4"}},{"id":2077570,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-12-22T18:56:00.000Z","date":"2022-12-20","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the \"Performance Condition\"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to \"double-trigger\" acceleration of vesting upon termination of employment following a change in control of the Registrant."}],"balance_after":300000,"derivative":{"exercise_price":22.57,"expiration_date":"2032-12-20","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001410939-22-000150","document":"wf-form4_167175334409918.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000150/wf-form4_167175334409918.xml","form_type":"4"}},{"id":2079643,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2022-12-20T19:02:59.000Z","date":"2022-12-18","kind":"exercise","acquired":false,"shares":36658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 18, 2020, the Reporting Person was granted an award of 146,630 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 18, 2020, the Reporting Person was granted an award of 146,630 restricted stock units, which vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."}],"balance_after":73314,"derivative":{"underlying":"Common Stock","underlying_shares":36658},"source":{"system":"sec-edgar","filing":"0001410939-22-000138","document":"wf-form4_167158096227025.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000138/wf-form4_167158096227025.xml","form_type":"4"}},{"id":2079642,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-12-20T19:02:59.000Z","date":"2022-12-19","kind":"sale","acquired":false,"shares":19457,"price":21.51,"value":418520.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the Reporting Person's minimum statutory withholding obligations with respect to the income recognized by the Reporting Person upon the vesting of the restricted stock units on December 18, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $21.19 to $21.95 on December 19, 2022 on behalf of a group of employees of the Registrant to satisfy the payment of withholding tax liability of such employees. The Reporting Person undertakes to provide upon request by the staff of the Securities Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":244138,"source":{"system":"sec-edgar","filing":"0001410939-22-000138","document":"wf-form4_167158096227025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000138/wf-form4_167158096227025.xml","form_type":"4"}},{"id":2079641,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-12-20T19:02:59.000Z","date":"2022-12-18","kind":"exercise","acquired":true,"shares":36658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":263595,"source":{"system":"sec-edgar","filing":"0001410939-22-000138","document":"wf-form4_167158096227025.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000138/wf-form4_167158096227025.xml","form_type":"4"}},{"id":2087837,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2022-12-13T21:01:19.000Z","date":"2022-12-12","kind":"exercise","acquired":false,"shares":22950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On December 12, 2018, the Reporting Person was granted 91,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment withthe Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On December 12, 2018, the Reporting Person was granted 91,800 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment withthe Registrant and the other terms and conditions of the Registrant's 2013 Stock Incentive Plan."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22950},"source":{"system":"sec-edgar","filing":"0001410939-22-000126","document":"wf-form4_167098326198515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000126/wf-form4_167098326198515.xml","form_type":"4"}},{"id":2087836,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Restricted Stock Units","published_at":"2022-12-13T21:01:19.000Z","date":"2022-12-09","kind":"exercise","acquired":false,"shares":23750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 9, 2019, the Reporting Person was granted an award of 95,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continuedemployment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 9, 2019, the Reporting Person was granted an award of 95,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continuedemployment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan."}],"balance_after":23750,"derivative":{"underlying":"Common Stock","underlying_shares":23750},"source":{"system":"sec-edgar","filing":"0001410939-22-000126","document":"wf-form4_167098326198515.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000126/wf-form4_167098326198515.xml","form_type":"4"}},{"id":2087835,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-12-13T21:01:19.000Z","date":"2022-12-12","kind":"exercise","acquired":true,"shares":22950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."}],"balance_after":226937,"source":{"system":"sec-edgar","filing":"0001410939-22-000126","document":"wf-form4_167098326198515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000126/wf-form4_167098326198515.xml","form_type":"4"}},{"id":2087834,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-12-13T21:01:19.000Z","date":"2022-12-09","kind":"exercise","acquired":true,"shares":23750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This total includes 548 shares acquired by the Reporting Person on September 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported."}],"balance_after":203987,"source":{"system":"sec-edgar","filing":"0001410939-22-000126","document":"wf-form4_167098326198515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000126/wf-form4_167098326198515.xml","form_type":"4"}},{"id":2124334,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-11-04T17:01:40.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":50000,"price":23.01,"value":1150500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sales reported on this Form 4 are the final shares to be sold under the above referenced Rule 10b5-1 trading plan. This plan is now terminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $22.54 to $23.65 per share on November 2, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":179689,"source":{"system":"sec-edgar","filing":"0001410939-22-000110","document":"wf-form4_166759567938998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000110/wf-form4_166759567938998.xml","form_type":"4"}},{"id":2236445,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-10T20:12:45.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant."}],"balance_after":45423,"derivative":{"exercise_price":8.55,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":45423},"source":{"system":"sec-edgar","filing":"0001209191-22-035852","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122035852/doc4.xml","form_type":"4"}},{"id":2236444,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-10T20:12:45.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":12671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of Restricted Stock Units (\"RSUs\"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock."}],"balance_after":71719,"source":{"system":"sec-edgar","filing":"0001209191-22-035852","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122035852/doc4.xml","form_type":"4"}},{"id":2253050,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2022-05-27T16:18:02.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":12790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":12790,"derivative":{"exercise_price":16.82,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-22-065913","document":"tm2217184-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065913/tm2217184-5_4seq1.xml","form_type":"4"}},{"id":2253049,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T16:18:02.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":7737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":23447,"source":{"system":"sec-edgar","filing":"0001104659-22-065913","document":"tm2217184-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065913/tm2217184-5_4seq1.xml","form_type":"4"}},{"id":2302390,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-06T18:11:19.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":50000,"price":18.7561,"value":937805.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. For a full discussion regarding the details of the Rule 10b5-1 trading plan adopted by the Reporting Person, refer to the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the the Securities and Exchange Commission on March 30, 2022."}],"balance_after":229689,"source":{"system":"sec-edgar","filing":"0001410939-22-000048","document":"wf-form4_164928306290708.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000048/wf-form4_164928306290708.xml","form_type":"4"}},{"id":2311146,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-01T19:03:34.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":40756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":325000,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":40756},"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311145,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-31","kind":"exercise","acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":365756,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311144,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-30","kind":"exercise","acquired":false,"shares":1213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":367156,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":1213},"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311143,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":40756,"price":17.5,"value":713230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.83 per share on April 1, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279689,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311142,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":40756,"price":2.94,"value":119822.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."}],"balance_after":320445,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311141,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-31","kind":"sale","acquired":false,"shares":1400,"price":17.02,"value":23828.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on March 31, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279689,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311140,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-31","kind":"exercise","acquired":true,"shares":1400,"price":2.94,"value":4116.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."}],"balance_after":281089,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311139,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-30","kind":"sale","acquired":false,"shares":1213,"price":17.004,"value":20625.852,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 30, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279689,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2311138,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-04-01T19:03:34.000Z","date":"2022-03-30","kind":"exercise","acquired":true,"shares":1213,"price":2.94,"value":3566.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022."}],"balance_after":280902,"source":{"system":"sec-edgar","filing":"0001410939-22-000040","document":"wf-form4_164885419748372.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000040/wf-form4_164885419748372.xml","form_type":"4"}},{"id":2315222,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-29T19:44:00.000Z","date":"2022-03-25","kind":"exercise","acquired":false,"shares":18775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was granted on December 19, 2017 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":368369,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":18775},"source":{"system":"sec-edgar","filing":"0001410939-22-000031","document":"wf-form4_164859742561860.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000031/wf-form4_164859742561860.xml","form_type":"4"}},{"id":2315221,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-29T19:44:00.000Z","date":"2022-03-25","kind":"sale","acquired":false,"shares":18775,"price":17.06,"value":320301.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.28 per share on March 25, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279689,"source":{"system":"sec-edgar","filing":"0001410939-22-000031","document":"wf-form4_164859742561860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000031/wf-form4_164859742561860.xml","form_type":"4"}},{"id":2315220,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-29T19:44:00.000Z","date":"2022-03-25","kind":"exercise","acquired":true,"shares":18775,"price":2.94,"value":55198.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."}],"balance_after":298464,"source":{"system":"sec-edgar","filing":"0001410939-22-000031","document":"wf-form4_164859742561860.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000031/wf-form4_164859742561860.xml","form_type":"4"}},{"id":2321173,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-22T16:43:18.000Z","date":"2022-03-18","kind":"exercise","acquired":false,"shares":3479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":387144,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":3479},"source":{"system":"sec-edgar","filing":"0001410939-22-000023","document":"wf-form4_164798177973672.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000023/wf-form4_164798177973672.xml","form_type":"4"}},{"id":2321172,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-22T16:43:18.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":3479,"price":17.0006,"value":59145.0874,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 18, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279689,"source":{"system":"sec-edgar","filing":"0001410939-22-000023","document":"wf-form4_164798177973672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000023/wf-form4_164798177973672.xml","form_type":"4"}},{"id":2321171,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-03-22T16:43:18.000Z","date":"2022-03-18","kind":"exercise","acquired":true,"shares":3479,"price":2.94,"value":10228.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This total includes 556 shares acquired by the Reporting Person on March 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported."}],"balance_after":283168,"source":{"system":"sec-edgar","filing":"0001410939-22-000023","document":"wf-form4_164798177973672.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000141093922000023/wf-form4_164798177973672.xml","form_type":"4"}},{"id":2348386,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-03-07T22:54:36.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the options were fully vested and exercisable as of the transaction date."}],"balance_after":0,"derivative":{"exercise_price":4.79,"expiration_date":"2022-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-016793","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122016793/doc4.xml","form_type":"4"}},{"id":2348385,"issuer":{"id":51196,"kind":"organization","name":"AMICUS THERAPEUTICS, INC.","symbol":"FOLD"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T22:54:36.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":15000,"price":4.79,"value":71850.0,"ownership":{"direct":true},"balance_after":59048,"source":{"system":"sec-edgar","filing":"0001209191-22-016793","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178879/000120919122016793/doc4.xml","form_type":"4"}},{"id":2454065,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-03T17:58:34.000Z","date":"2021-12-31","kind":"exercise","acquired":false,"shares":801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":390623,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":801},"source":{"system":"sec-edgar","filing":"0001104659-22-000502","document":"tm221330-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465922000502/tm221330-1_4seq1.xml","form_type":"4"}},{"id":2454064,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-03T17:58:34.000Z","date":"2021-12-30","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date."}],"balance_after":391424,"derivative":{"exercise_price":2.94,"expiration_date":"2027-12-18","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001104659-22-000502","document":"tm221330-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465922000502/tm221330-1_4seq1.xml","form_type":"4"}},{"id":2454063,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-01-03T17:58:34.000Z","date":"2021-12-31","kind":"sale","acquired":false,"shares":801,"price":17.005,"value":13621.005,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.02 per share on December 31, 2021. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range."}],"balance_after":279133,"source":{"system":"sec-edgar","filing":"0001104659-22-000502","document":"tm221330-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465922000502/tm221330-1_4seq1.xml","form_type":"4"}},{"id":2454062,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-01-03T17:58:34.000Z","date":"2021-12-31","kind":"exercise","acquired":true,"shares":801,"price":2.94,"value":2354.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."}],"balance_after":279934,"source":{"system":"sec-edgar","filing":"0001104659-22-000502","document":"tm221330-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465922000502/tm221330-1_4seq1.xml","form_type":"4"}},{"id":2454061,"issuer":{"id":111416,"kind":"organization","name":"IVERIC bio, Inc.","symbol":"ISEE"},"owners":[{"id":36737,"kind":"person","name":"SBLENDORIO GLENN","position":1,"cik":"0001277478","reported_name":"SBLENDORIO GLENN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2022-01-03T17:58:34.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":100,"price":17.01,"value":1701.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021."}],"balance_after":279133,"source":{"system":"sec-edgar","filing":"0001104659-22-000502","document":"tm221330-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1410939/000110465922000502/tm221330-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2022-01-03T17:58:34.000000Z,2454061"}